Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.

Rheumatology (Oxford, England)

Volumn 50, Issue 6, 2011, Pages 1148-1152

  Conti, Fabrizio ^a   Ceccarelli, Fulvia ^b   Perricone, Carlo ^b   Alessandri, Cristiano ^b   Conti, Virginia ^b   Massaro, Laura ^b   Truglia, Simona ^b   Spinelli, Francesca R ^b   Spadaro, Antonio ^b   Valesini, Guido ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG TOXICITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NONPARAMETRIC TEST; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SAFETY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK ASSESSMENT; SAFETY MANAGEMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857475922     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq436     Document Type: Article

References (0)